Iovance Biotherapeutics, Inc.
IOVA
Rang in Aktien
#2783
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Aktienkurs
$14.90
Marktkapitalisierung
$6.75B
Veränderung (1 Tag)
4.82%
Veränderung (1 Jahr)
542.03%
Land
US
Handel Iovance Biotherapeutics, Inc. (IOVA)
Kategorie
Healthcare
Gewinn für Iovance Biotherapeutics, Inc. (IOVA)
Gewinn im Jun 2026 TTM: $-293.78M
Laut den aktuellen Finanzberichten von Iovance Biotherapeutics, Inc. betragen die aktuellen Gewinne des Unternehmens $-293.78M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-447.52M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $-395.89M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Iovance Biotherapeutics, Inc. von 2008 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-293.78M | -21.66% |
| 2024 | $-375.01M | -16.20% |
| 2023 | $-447.52M | 13.04% |
| 2022 | $-395.89M | 15.67% |
| 2021 | $-342.25M | 31.85% |
| 2020 | $-259.58M | 31.40% |
| 2019 | $-197.56M | 59.86% |
| 2018 | $-123.58M | 34.23% |
| 2017 | $-92.06M | 74.05% |
| 2016 | $-52.89M | 91.23% |
| 2015 | $-27.66M | 129.83% |
| 2014 | $-12.04M | -52.58% |
| 2013 | $-25.38M | 667.26% |
| 2012 | $-3.31M | -87.13% |
| 2011 | $-25.69M | 1,497.89% |
| 2010 | $-1.61M | 10,095.28% |
| 2009 | $-15.77K | -72.40% |
| 2008 | $-57.14K | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | -1,895.55% |
US
|
|
| $-3.09B | 950.80% |
US
|
|
| $-4.02B | 1,267.09% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -763.99% |
NL
|
